Table 6.
Characteristics of L-arginine/NO pathway metabolites as CRC biomarkers in the general asymptomatic population.
| Marker | Criterion | Sens. and Spec. | Youden (J) Index | LR+ and LR− |
|---|---|---|---|---|
| Arg | >153.2 µM | 40.2 and 83.3% | 0.245 | 2.4 and 0.72 |
| ADMA | >0.580 µM | 49.6 and 83.3% | 0.330 | 3.0 and 0.60 |
| SDMA | >0.507 µM | 69.3 and 79.6% | 0.490 | 3.4 and 0.38 |
| Cit | ≤70.2 µM | 87.6 and 46.3% | 0.339 | 1.6 and 0.27 |
| DMA | >62.6 µM | 51.1 and 85.2% | 0.363 | 3.5 and 0.57 |
| Panel 1 | >0.54 2 | 95.6 and 74.1% | 0.697 | 3.7 and 0.06 |
CRC: Colorectal cancer; Sens.: Sensitivity; Spec.: Specificity; LR: Likelihood ratios; Arg: Arginine; ADMA: Asymmetric dimethylarginine; SDMA: Symmetric dimethylarginine; Cit: Citrulline; DMA: Dimethylamine; 1 a metabolite panel consisting of SDMA, Cit, and DMA—metabolites selected in the logistic regression analysis as variables independently from others associated with CRC; 2 predicted probabilities.